 |
市场调查报告书
商品编码
1705950
全球支气管扩张剂市场按药物类别、给药途径、适应症、分销管道和地区划分Global Bronchodilators Market, By Drug Class, By Route of Administration, By Indication, By Distribution Channel, By Geography . |
||||||
价格
简介目录
2025 年全球支气管扩张剂市场规模估计为 228.7 亿美元，预计到 2032 年将达到 296.9 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 3.8%。
| 报告范围 | 报告详细信息 | ||
|---|---|---|---|
| 基准年 | 2024 | 2025年的市场规模 | 228.7亿美元 |
| 效能数据 | 2020-2024 | 预测期 | 2025-2032 |
| 预测期：2025-2032年复合年增长率： | 3.80% | 2032年价值预测 | 296.9亿美元 |
数字。 2025年全球市场占有率（%）
支气管扩张剂是一种可以打开肺部气道、使呼吸更顺畅的药物。支气管扩张剂透过放鬆和扩张支气管周围的平滑肌起作用，有助于缓解喘息、咳嗽、呼吸急促以及与气喘和慢性阻塞性肺病(COPD) 等呼吸系统疾病相关的其他症状。支气管扩张剂有短效型和长效型，短效型用于短期缓解突发性呼吸困难，长效型则常用于控制气喘和慢性阻塞性肺病的呼吸困难，并增强皮质类固醇对气喘的作用。抗胆碱药物（也称为抗毒蕈碱药物）主要用于治疗 COPD，但有些也可用于治疗气喘。抗胆碱能药物透过阻断胆碱能神经来打开气道。支气管扩张剂的副作用因特定药物而异。支气管扩张剂的常见副作用包括手震、头痛、肌肉痉挛、噁心/呕吐和腹泻等。
市场动态：
全球支气管扩张剂市场的成长受到多种因素的推动，例如老龄人口增加（他们更容易患呼吸系统疾病）、都市区环境污染水平上升以及对气喘和慢性阻塞性肺病 (COPD) 正确管理的认识不断提高。然而，替代治疗方案的可用性、长期使用支气管扩张剂的副作用以及重磅药物的专利到期是预计会抑制市场成长的一些主要因素。联合治疗（可同时使用两种或两种以上的药物）的发展为该市场的公司创造了新的机会。此外，为了更好地控制呼吸道症状，更加重视预防性吸入疗法可能会推动未来的需求。
本研究的主要特点
- 本报告对全球支气管扩张剂市场进行了详细分析，并提供了预测期（2025-2032）的市场规模和年复合成长率(CAGR)，假设 2024 年为基准年。
- 它还强调了各个领域的潜在商机，并说明了该市场的有吸引力的投资提案矩阵。
- 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的重要见解。
- 该报告涵盖了全球支气管扩张剂市场的主要企业概况，基于公司亮点、产品系列、主要产品亮点、财务表现和策略等参数。涉及的主要公司包括葛兰素史克公司 (GSK plc.)、Astra Zeneca)、迈兰公司 (Mylan NV)、默克公司 (Merck & Co.)、太阳製药工业公司 (Sun Pharmaceutical Industries, Inc.)、Glenmark、诺华公司 (Novartis AG)、国际梯瓦 (Beva Industries)、国际工业製药公司 (Boehr)、国际工业公司 (Boeva). Inc.)、西普拉 (Cipla)、Sunovion Pharmaceuticals, Inc.、赛诺菲 (Sanofi) 和 Innoviva。
- 本报告的见解将使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
- 全球支气管扩张剂市场报告迎合了该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
- 相关人员将透过用于分析全球支气管扩张剂市场的各种策略矩阵更轻鬆地做出决策。
目录
第一章 调查目的与前提条件
- 研究目标
- 先决条件
- 简称
第二章 市场展望
- 报告描述
- 市场定义和范围
- 执行摘要
- Coherent Opportunity Map（COM）
第三章市场动态、法规与趋势分析
- 市场动态
- 提高产品核可
- 严格的法规环境
- 加强宣传宣传活动
- 主要亮点
- 监管情景
- 市场趋势
- 管道分析
- 产品发布/核准
- PEST分析
- 波特分析
- 流行病学
- 治疗流程（病人历程）
- 治疗方案分析
- 主要市场参与者的新投资
- 定价分析
- 疾病意识计划
- 分析治疗的安全性和有效性
- 合併、收购和合作
4. 全球支气管扩张剂市场-COVID-19 疫情的影响
- COVID-19流行病学
- 供需侧分析
- 经济影响
5. 2020-2032 年全球支气管扩张剂市场（依药物类别）
- β-肾上腺素能支气管扩张剂
- 黄嘌呤衍生物
- 抗胆碱能支气管扩张剂
6. 全球支气管扩张剂市场（依给药途径），2020-2032 年
- 口服
- 鼻腔（可吸入）
- 注射
7. 全球支气管扩张剂市场（依适应症划分），2020 年至 2032 年
- 气喘
- 慢性阻塞性肺病（COPD）
- 其他（慢性支气管炎等）
8. 2020-2032 年全球支气管扩张剂市场（依通路）
- 医院药房
- 零售药局
- 网路药局
9. 2020-2032 年全球支气管扩张剂市场（按地区）
- 北美洲
- 欧洲
- 亚太地区
- 拉丁美洲
- 中东
- 非洲
第十章 竞争格局
- 公司简介
- GSK plc.
- Mylan NV
- Mylan NV
- Merck &Co., Inc.
- Sun Pharmaceutical Industries Ltd.
- Glenmark Pharmaceuticals Limited
- Novartis AG
- Boehringer Ingelheim International GmbH
- Teva Pharmaceutical Industries Ltd.
- Cipla Inc.
- Sunovion Pharmaceuticals Inc.
- Sanofi
- Innoviva
第 11 章 章节
- 参考
- 调查方法
- 关于出版商
简介目录
Product Code: CMI6679
Global Bronchodilators Market is estimated to be valued at USD 22.87 Bn in 2025 and is expected to reach USD 29.69 Bn by 2032, growing at a compound annual growth rate (CAGR) of 3.8% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 22.87 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 3.80% | 2032 Value Projection: | USD 29.69 Bn |
Figure. Global Bronchodilators Market Share (%), By Region 2025
Bronchodilators are medications that help open up the airways in the lungs to allow for easier breathing. They work by relaxing and dilating the smooth muscles surrounding the bronchial tubes, thus reducing wheezing, coughing, shortness of breath and other symptoms associated with respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD). Bronchodilators may be either short-acting used as short-term relief from sudden, unexpected attacks of breathlessness or long-acting used regularly to help control breathlessness in asthma and COPD, and increase the effectiveness of corticosteroids in asthma. Anticholinergics (also known as antimuscarinics) are mainly used to treat COPD, but a few can also be used for asthma. Anticholinergics cause the airways to widen by blocking the cholinergic nerves. The side effects of bronchodilators can vary, depending on the specific medication. General side effects of bronchodilators include trembling, particularly in the hands, headache, muscle cramps, nausea and vomiting, diarrhea, etc.
Market Dynamics:
The global bronchodilators market growth is driven by factors such as the growing geriatric population which is more susceptible to respiratory diseases, increased environmental pollution levels in both urban and rural areas, and rising awareness about proper management of asthma and COPD. However, availability of alternative treatment options, side effects associated with long term use of bronchodilators, and patent expires of blockbuster drugs are some of the key factors expected to restrain market growth. Development of combination therapies that can deliver two or more drugs simultaneously is opening new opportunities for players in this market. Moreover, greater emphasis on preventive inhalation therapies for better management of respiratory symptoms will drive future demand.
Key features of the study:
- This report provides in-depth analysis of the global bronchodilators market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global bronchodilators market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies - Key companies covered as a part of this study include GSK plc., AstraZeneca, Mylan N.V., Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Novartis AG, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Cipla Inc., Sunovion Pharmaceuticals Inc., Sanofi and Innoviva
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global bronchodilators market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bronchodilators market
Detailed Segmentation:
- Global Bronchodilators Market, By Drug Class
- Beta-adrenergic Bronchodilators
- Xanthine Derivatives
- Anticholinergic Bronchodilators
- Global Bronchodilators Market, By Route of Administration
- Oral
- Nasal (inhalable)
- Injectable
- Global Bronchodilators Market, By Indication
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Others (Chronic bronchitis, etc.)
- Global Bronchodilators Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Bronchodilators Market, By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
- Company Profiles
- GSK plc.
- AbbVie Inc.
- AstraZeneca
- Mylan N.V.
- Merck & Co., Inc.
- Sun Pharmaceutical Industries Ltd.
- Glenmark Pharmaceuticals Limited
- Novartis AG
- Boehringer Ingelheim International GmbH
- Teva Pharmaceutical Industries Ltd.
- Cipla Inc.
- Sunovion Pharmaceuticals Inc.
- Sanofi
- Innoviva
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Indication
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Increasing Product Approval
- Stringent Regulatory Environment
- Increasing Awareness Campaigns
- Key Highlights
- Regulatory Scenario
- Market Trends
- Pipeline Analysis
- Product Launch/Approval
- PEST Analysis
- PORTER's Analysis
- Epidemiology
- Treatment Algorithm (Patient Journey)
- Treatment Option Analysis
- New Investments by Major Market Players
- Pricing Analysis
- Disease Awareness Programs
- Treatment Safety and Efficacy Analysis
- Mergers, Acquisitions, and Collaborations
4. Global Bronchodilators Market- Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global Bronchodilators Market, By Drug Class, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Beta-adrenergic Bronchodilators
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Xanthine Derivatives
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Anticholinergic Bronchodilators
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
6. Global Bronchodilators Market, By Route of Administration, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Nasal (inhalable)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
7. Global Bronchodilators Market, By Indication, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Asthma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Chronic Obstructive Pulmonary Disease (COPD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Others (Chronic bronchitis, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
8. Global Bronchodilators Market, By Distribution Channel, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 201s9-2032, (US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
9. Global Bronchodilators Market, By Region, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, By Country, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Country, 2021 -2032
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032, (US$ Bn)
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- Company Profile
- GSK plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Glenmark Pharmaceuticals Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Boehringer Ingelheim International GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Cipla Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sunovion Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Innoviva
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
11. Section
- References
- Research Methodology
- About us
